Rybrevant Faspro™（Amivantamab与Hyaluronidase-Lpuj）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，该认定针对的是晚期头颈癌患者群体。这一重要进展为治疗这一难治性癌症提供了新的希望。
Rybrevant Faspro™（Amivantamab与Hyaluronidase-Lpuj）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，该认定针对的是晚期头颈癌患者群体。这一重要进展为治疗这一难治性癌症提供了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.